[go: up one dir, main page]

GT200900037A - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
GT200900037A
GT200900037A GT200900037A GT200900037A GT200900037A GT 200900037 A GT200900037 A GT 200900037A GT 200900037 A GT200900037 A GT 200900037A GT 200900037 A GT200900037 A GT 200900037A GT 200900037 A GT200900037 A GT 200900037A
Authority
GT
Guatemala
Prior art keywords
organic compounds
hydroxi
crystal
dietil
etil
Prior art date
Application number
GT200900037A
Other languages
English (en)
Inventor
Lohse Olivier
Monnier Stephanie
Jordine Guido
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900037(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200900037A publication Critical patent/GT200900037A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA NUEVA FORMA DE CRISTAL POLIMORFICA DE MALEATO DE (R)-5-[2-(5,6-DIETIL-INDAN-2-IL-AMINO)-1-HIDROXI-ETIL]-8-HIDROXI-1H-QUINOLIN-2-ONA, DESIGNADA COMO LA FORMA DEL CRISTAL Q ALFA Y A METODOS PARA SU PREPARACION SIENDO DE UTILIDAD EN CUADROS DE ENFERMEDADES RESPIRATORIAS.
GT200900037A 2006-08-31 2009-02-20 Compuestos organicos GT200900037A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119895A EP1914227A1 (en) 2006-08-31 2006-08-31 Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist

Publications (1)

Publication Number Publication Date
GT200900037A true GT200900037A (es) 2010-03-11

Family

ID=37714644

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900037A GT200900037A (es) 2006-08-31 2009-02-20 Compuestos organicos

Country Status (21)

Country Link
US (1) US20100010039A1 (es)
EP (2) EP1914227A1 (es)
JP (1) JP2010501631A (es)
KR (1) KR20090049615A (es)
CN (1) CN101511794A (es)
AR (1) AR063698A1 (es)
AU (1) AU2007291270A1 (es)
BR (1) BRPI0716383A2 (es)
CA (1) CA2659144A1 (es)
CL (1) CL2007002525A1 (es)
GT (1) GT200900037A (es)
IL (1) IL196805A0 (es)
MA (1) MA30763B1 (es)
MX (1) MX2009002301A (es)
NO (1) NO20091234L (es)
PE (1) PE20080923A1 (es)
RU (1) RU2009111389A (es)
TN (1) TN2009000056A1 (es)
TW (1) TW200817333A (es)
WO (1) WO2008025816A1 (es)
ZA (1) ZA200900264B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481738A1 (en) * 2009-09-25 2012-08-01 Kyorin Pharmaceutical Co., Ltd. Maleic acid salt and crystal thereof
WO2014154841A1 (en) 2013-03-27 2014-10-02 Laboratorios Lesvi, S.L. Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
CN103830195A (zh) * 2014-03-11 2014-06-04 熊妲妮 一种茚达特罗片及其制备方法
CN103830193A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗片制剂及其制备方法
EP3347345B1 (en) 2015-09-29 2019-07-31 Inke, S.A. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP2066639A1 (en) 2009-06-10
CN101511794A (zh) 2009-08-19
WO2008025816A1 (en) 2008-03-06
KR20090049615A (ko) 2009-05-18
CA2659144A1 (en) 2008-03-06
MA30763B1 (fr) 2009-10-01
EP1914227A1 (en) 2008-04-23
TW200817333A (en) 2008-04-16
MX2009002301A (es) 2009-03-20
IL196805A0 (en) 2009-11-18
AR063698A1 (es) 2009-02-11
JP2010501631A (ja) 2010-01-21
RU2009111389A (ru) 2010-10-10
US20100010039A1 (en) 2010-01-14
CL2007002525A1 (es) 2008-07-11
PE20080923A1 (es) 2008-07-11
TN2009000056A1 (en) 2010-08-19
BRPI0716383A2 (pt) 2013-09-24
AU2007291270A1 (en) 2008-03-06
ZA200900264B (en) 2010-05-26
NO20091234L (no) 2009-03-30

Similar Documents

Publication Publication Date Title
CY2020032I2 (el) Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια
DK3309139T3 (da) Process for the preparation of 2,3,3,3-trifluoropropene
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
ITMI20071260A1 (it) Procedimento di produzione di forme per la fabbricazione di calzature
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
EP2211620A4 (en) THERAPEUTIC COMPOUNDS
EP2320907A4 (en) THERAPEUTIC COMPOUNDS
ECSP099817A (es) Procesos para la preparacion de pirazoles
LT3133070T (lt) Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui
BRPI0922904A2 (pt) "compostos"
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
ECSP11011151A (es) Compuestos purina
EP2268285A4 (en) THERAPEUTIC COMPOUNDS
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
BRPI0821102A2 (pt) Preparação de derivados de di-hidropirrol como intermediários
EP2164324A4 (en) THERAPEUTIC COMPOUNDS
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
SE0800742L (sv) Vikttäcke
GT200900037A (es) Compuestos organicos
PL2293805T3 (pl) Kompozycja do ssania, do leczenia chorób zapalnych jamy ustnej i gardłowej
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida